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Summary
The skin and mucosal epithelia of humans and other mammals are per-
manently colonized by large microbial communities (the microbiota). Due
to this life-long association with the microbiota, these microbes have an
extensive influence over the physiology of their host organism. It is now
becoming apparent that nearly all tissues and organ systems, whether in
direct contact with the microbiota or in deeper host sites, are under
microbial influence. The immune system is perhaps the most profoundly
affected, with the microbiota programming both its innate and adaptive
arms. The regulation of immunity by the microbiota helps to protect the
host against intestinal and extra-intestinal infection by many classes of
pathogen. In this review, we will discuss the experimental evidence sup-
porting a role for the microbiota in regulating host defences to extra-
intestinal infection, draw together common mechanistic themes, including
the central role of pattern recognition receptors, and outline outstanding
questions that need to be answered.
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Introduction
The human microbiota is composed of myriad archaea,
bacteria, eukaryotes and viruses.1,2 It contains approxi-
mately 1013–1014 bacteria that colonize environmentally
exposed surfaces.3,4 Colonization begins in earnest after
birth, with the mother normally providing the bacterial
inoculum that seeds the microbiota of her offspring.4,5
Initially, the bacterial communities of each surface have a
similar taxonomic composition, but through the course
of infancy each surface develops a microbiota with a
unique composition that stabilizes during adulthood.2,6,7
In the adult gastrointestinal tract, the microbiota is domi-
nated by bacteria from two phyla: the Bacteroidetes and
Firmicutes.3 There are representatives from other bacterial
phyla, including Proteobacteria and Acintobacteria, but
they form only a minor fraction of the bacterial taxa pre-
sent.1,3 It is thought that many of the members of the
Bacteroidetes and Firmicutes are only found within the
mammalian gastrointestinal tract, suggesting that these
organisms have become specialized to live within this
niche and have evolved to form a stable, long-term inter-
action with their host.1 Other host surfaces colonized by
large bacterial communities include the airway and
skin.2,6 The upper airway has a rich microbial community
dominated by bacteria from the Firmicute, Actinobacteria
and Proteobacteria phyla,8 with the skin being home to
mainly Actinobacteria, Proteobacteria and Firmicutes.2
Throughout life, diet9,10 and host genetics11,12 are thought
to play a role in shaping microbiota composition, with
infection13–15 and antibiotic treatment16–19 being exam-
ples of major causes of microbiota disruption (dysbiosis).
The main host system for interacting with the micro-
biota is the immune system. At the mucosa the micro-
biota is in constant, close, contact with both innate and
adaptive immune cells.20–22 This promotes the develop-
ment and maturation of the mucosal immune system.20,22
The resulting agglomeration of immune cells and struc-
tures helps to manage and contain the microbiota at the
mucosa.23,24 The microbiota also drives the maturation of
systemic immunity beyond the confines of the mucosa,
including in major immune tissues such as the bone mar-
row and spleen.25–30 The importance of host–microbiota
interactions for our health has been highlighted by clini-
cal studies and work with animal models demonstrating
that microbiota dysbiosis is associated with diseases and
immune dysfunctions in both intestinal and extra-intest-
inal tissues. These include chronic inflammatory condi-
tions in the intestine,31,32 autoimmunity33–35 and
increased susceptibility to intestinal and extra-intestinal
infections.15,30,32,36–43
The mechanisms by which the microbiota helps to pro-
tect against intestinal infection are increasingly well
understood. Within the intestine the microbiota
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stimulates epithelial production of antimicrobial pep-
tides,44–46 in addition to promoting the antimicrobial
activity of immune cells.47 These mechanisms of micro-
biota-mediated protection against intestinal infection have
been extensively reviewed elsewhere15,38,48 and will not be
discussed in this article. How the microbiota helps to
protect against infection at sites outside the intestine (ex-
tra-intestinal), in contrast, is only just becoming clear
and is the focus of this review.
Host resistance to airway infection and the
microbiota
Of all extra-intestinal infections, infection of the respira-
tory tract is the foremost cause of morbidity and mortal-
ity worldwide.49 The respiratory tract is a major
environmental interface, beginning at the nares of the
upper airway extending down to the alveoli in the lower
airway (lung). The physiology of the lower airway reflects
its role in respiration, with strong pressures to maintain
the integrity of the delicate alveoli and to allow efficient
gaseous exchange. The lower airway is therefore main-
tained in a quiescent state to minimize unnecessary
inflammation. On occasion, however, microbes that have
a commensal lifestyle in the upper airway, including
Streptococcus pneumoniae, Staphylococcus aureus and Hae-
mophilus influenzae, do reach the lower airway, often
resulting in pneumonia.8,50 Lower airway defences must
therefore be able to rapidly eliminate these microbes
before they cause airway damage and threaten host
integrity.
In the lower airway, initial defences are led by the
epithelium and alveolar macrophages, the tissue macro-
phages of the lung.51–53 Alveolar macrophages perform a
variety of functions, including preventing unnecessary
inflammation, eliminating pathogens, and restoring lung
homeostasis after infection.54 As infection proceeds, alve-
olar macrophages and epithelial defences are bolstered by
the recruitment of specialized antimicrobial cells includ-
ing neutrophils and natural killer cells.53 These innate
effectors are supplemented by lung dendritic cells that
transport antigen to draining lymph nodes for the devel-
opment of adaptive responses, which are crucial for the
clearance of many respiratory pathogens.53 Central to the
coordination of all these airway defences is initial micro-
bial recognition by pattern recognition receptors (PRRs)
leading to the production of a variety of signalling mole-
cules.52,55 These include type I interferons during viral
infection,56 and cytokines such as granulocyte–macro-
phage colony-stimulating factor, interleukin-22 (IL-22),
IL-23 and IL-17, which orchestrate both innate and adap-
tive antibacterial immunity.51–53,57 Innate defences against
infection have generally been considered ‘hard-wired’ – a
specific infection will elicit a defined, stereotypical
immune response.58–60 There has been a gradual re-
evaluation of this thinking because a variety of studies
have shown that the host’s resident microbes shape
numerous aspects of host defences to airway infection.
A number of recent studies have demonstrated that the
microbiota enhances the initial innate response to lung
infection by bacteria.37,42,61,62 One study showed that
microbiota-depleted mice had significant defects in early
clearance (6 hr post-infection) of Klebsiella pneumoniae
from the lung, compared with mice with a microbiota.42
This correlated with decreased production of the inflam-
matory cytokines IL-6 and tumour necrosis factor-a.
Attenuated bacterial clearance was the result of reduced
production of reactive oxygen species by alveolar macro-
phages decreasing bacterial killing by these cells. Adminis-
tration of Nod-like receptor (Nod1 or Nod2) ligands by
oral gavage, but not intranasally, restored lung defences
in microbiota-depleted mice, demonstrating the impor-
tance of PRR signalling in these phenomena.42 Other
studies have demonstrated that in mice without a micro-
biota (germ-free) K. pneumoniae lung infection causes
significantly higher rates of mortality than in mice with a
microbiota.62 Similar defects in lung defences were also
seen in a model of Escherichia coli lung infection.63 This
suggests that microbes in the gastrointestinal tract can
have a systemic influence on antibacterial defences at dis-
tal mucosal sites and this occurs through PRR activation.
A further study corroborated and extended this work
by showing that the microbiota enhances host resistance
to pneumococcal pneumonia.37 In this work, microbiota-
depleted mice had increased bacterial loads in the lung
and spleen after intranasal infection with S. pneumoniae,
compared with mice with a microbiota. As with the pre-
vious study, these defects in host defences were evident
6 hr into lung infection with S. pneumoniae and acceler-
ated the mortality rate of microbiota-depleted animals. In
the absence of the microbiota, phagocytosis of S. pneumo-
niae by alveolar macrophages was reduced, suggesting
that it was defects in these innate cells that lead to atten-
uated antibacterial defences. Pneumococcal clearance and
cytokine responses in the lung were restored in micro-
biota-depleted mice if they were administered faeces from
mice with a normal microbiota before lung infection.37
From these studies it is clear that the bactericidal capacity
of alveolar macrophages is regulated by signals from the
microbiota and these long-lived tissue-resident cells are
therefore constantly gauging and responding to the host’s
microbial environment.
The influence of the microbiota is not limited to regu-
lating antibacterial immunity, work has now demon-
strated that it also promotes antiviral defences in the
lung.41 Microbiota-depleted mice infected with influenza
have higher viral titres in the lung, compared with mice
with a microbiota. Similarly to defects in antibacterial
immunity, there was reduced lung cytokine production
during infection, specifically IL-18 and IL-1b which are
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produced downstream of inflammasome activation. In
the absence of the microbiota, there was reduced den-
dritic cell migration from the lung to the mediastinal
lymph nodes, which was associated with reduced T-cell
responses and reduced influenza-specific antibody pro-
duction. These defects could be rescued by administration
of Toll-like receptor ligands via the airway or intrarectally
into the gastrointestinal tract. Within the microbiota, it
was found that a group of neomycin-sensitive bacteria are
a sufficient stimulus to enhance antiviral defences in the
lung.41 Collectively, the studies demonstrate that defences
against respiratory infection by major bacterial and viral
pathogens are fortified by the microbiota.
The fact that depletion of a neomycin-sensitive popula-
tion of bacteria in the microbiota was sufficient to reduce
resistance to influenza infection suggests that not all
members of the microbiota have an equivalent effect on
extra-intestinal defences to infection. This hypothesis is
supported by a study showing that mice with segmented
filamentous bacteria (SFB) in the gastrointestinal tract
survive Staphylococcus aureus pneumonia better than
those without.61 SFB are known to regulate T-cell differ-
entiation in the murine intestine, which protects against
intestinal infection,47 but this new work demonstrates
that SFB also play a wider role in enhancing extra-intest-
inal host defences. After intranasal infection with methi-
cillin-resistant Staphylococcus aureus, SFB-negative mice
had higher bacterial burdens in the lung and spleen, com-
pared with SFB-positive mice.61 Mice colonized with SFB
had increased numbers of IL-22-producing cells in the
lung, a cytokine known to enhance epithelial barrier
integrity and drive the production of antimicrobial pep-
tides crucial for mucosal defences.64 The importance of
this cytokine was demonstrated by experiments showing
that addition of recombinant IL-22 to SFB-negative mice
rescued defects in lung immunity caused by the absence
of SFB, and neutralization of IL-22 in SFB-positive mice
abrogated any differences between SFB-positive and SFB-
negative animals. If SFB-negative mice were made SFB-
positive by co-housing with SFB-positive mice, or by oral
gavage with SFB-positive faeces, their defences against
staphylococcal pneumonia were enhanced.61 Hence, dif-
fering microbiota compositions can have a significant
impact on the host’s resistance to extra-intestinal
infection.
Administration of PRR ligands or bacteria via the oral
and rectal routes suggests that distal microbial signals can
regulate lung immunity.37,41,42,61 In addition to these dis-
tal signals, local microbes from the upper airway have
also been demonstrated to regulate lower airway immu-
nity.41,65 It has been shown that mice maintained in
specific pathogen-free (SPF) conditions are more suscep-
tible to influenza infection than those maintained in non-
SPF conditions.65 A distinctive feature of the non-SPF
mice used in this study was the higher load of commensal
bacteria in the upper airway with a common colonizer of
the upper airway in non-SPF mice being Staphylococcus
aureus. Treatment of mice with this bacterium before
influenza inoculation reduced lung damage during influ-
enza infection. Mechanistically, this protection was due to
the recruitment of monocytes from the blood, which sub-
sequently differentiated into anti-inflammatory M2 alveo-
lar macrophages in the lung.65 These macrophages inhibit
the recruitment of excessive inflammatory cells during
infection and it is thought that this reduces tissue damage
and mortality caused by influenza.
Host resistance to systemic infection and the
microbiota
The major portal of entry for most pathogenic microbes
is the mucosa. Mucosal defences are highly effective at
neutralizing and eliminating the majority of infectious
threats the host encounters. Periodically, however, dan-
gerous microbes can survive mucosal defences, gain entry
into the circulation and then disseminate to non-mucosal
tissues throughout the body. In these circumstances the
host relies on bloodstream defences and blood filtering
organs such as the spleen and liver to scavenge invading
microbes. As non-mucosal organs and tissues are not
directly exposed to the environment they are not thought
to be colonized by a microbiota. Because of the lack of
direct contact with live microbes, it has long been pre-
sumed that the microbiota does not influence these sys-
temic defences. We now know that this assumption is
incorrect and that the production and function of cells
that constitute systemic defences is greatly influenced by
the microbiota.29,30,39,66–68
Neutrophils are a major innate cell population in the
bloodstream and are produced in the bone marrow
before release into the blood. Numerous studies have
shown that microbiota-depleted mice produce signifi-
cantly fewer neutrophils than mice with a micro-
biota.39,67,69,70 Reduced neutrophil production renders
these animals more susceptible to systemic infection by
numerous bacteria including E. coli and Listeria monocy-
togenes.39,69 Studies have shown that recognition of bacte-
ria and/or bacterial products from the microbiota by
PRRs is the first step in driving this microbiota-depen-
dent increase in neutrophil production.67,69 This PRR
activation is not restricted to a single site, as PRR ligands
in the circulation and at the mucosa are able to drive
increased neutrophil production.67,69 The signals required
downstream of PRRs, in contrast, are less well defined. A
number of studies have shown that IL-17 is important, as
are members of the colony-stimulating factor family.67 In
addition to neutrophils, the production of macrophages
and monocytes in the spleen is also promoted by the
microbiota through currently poorly understood mecha-
nisms.39 Hence, one of the most fundamental decisions
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made by the immune system – determining the number
of innate cells required to safeguard the host from micro-
bial assault – is directly regulated by the microbiota.
It is not only the production of innate cells that is con-
trolled by the microbiota, but also the functioning of
these cells. It has been demonstrated that the ability of
neutrophils to migrate into tissues in response to inflam-
matory signals is attenuated after microbiota depletion,71
as is their bactericidal activity.29,37 Again, both of these
phenomena require PRR activation mediated by Toll-like
receptors in the case of extravasation71 and Nod-like
receptors to enhance bacterial killing.29 Currently, the
exact mechanisms of neutrophil killing promoted by the
microbiota are unknown. Cytokine production by sys-
temic macrophages and dendritic cell populations is also
regulated by the microbiota.68 Reduced cytokine produc-
tion by these cells in the spleen, particularly reduced type
I interferon, leads to attenuated host defences against sys-
temic viral infection.68 During systemic lymphocytic
choriomeningitis virus infection, this microbiota-depen-
dent enhancement of type I interferon production by
dendritic cells primes a more robust NK cell response.68
This promotes viral eradication from the spleen. Again,
the priming effect of the microbiota was mediated by
PRR activation.68 Similarly, the microbiota enhances
clearance of hepatitis B virus in the liver.72 This is
thought to be due to signals from the microbiota enhanc-
ing both the cellular and humoral response to HBV infec-
tion. The mechanistic basis for this, however, remains to
be determined.
Host resistance to infection in the central
nervous system and the microbiota
Alveolar and splenic macrophages are not the only
macrophage populations under the influence of the
microbiota. Microglia, the tissue macrophages of the cen-
tral nervous system parenchyma, and the main innate cell
population at this site,73 have also recently been shown to
respond to signals from the microbiota.74 Their position
in the central nervous system means that they are distal
to sites of direct microbial colonization and hidden
behind the protection of the blood–brain barrier.73
Microglia from mice without a microbiota have reduced
expression of many genes connected to host defence
including those involved in interleukin and mitogen-acti-
vated protein kinase signalling pathways.74 These micro-
glia also expressed high levels of CSF1, F4/80 and CD31,
in comparison to microglia from mice with a microbiota.
These markers are known to be down-regulated as micro-
glia mature, which suggests that the microbiota drives the
maturation of these cells. As a consequence of this, in the
absence of the microbiota, the microglia-mediated
response to inflammation and viral infection is defective.
Reintroduction of the normal murine microbiota rescued
defects in microglia function. Restoration of a limited
number of bacterial species to mice without a microbiota,
however, only partially rescued defects caused by lack of
microbial stimulation.74 This suggests that complete
immune maturation of the microglia requires a complex
microbiota and/or specific bacterial groups within the
microbiota. This complements studies of neutrophil pro-
duction that have also shown that a complex microbiota
is a more potent stimulus of neutrophil production than
a microbiota of only a limited number of bacterial spe-
cies.69 Short-chain fatty acids, which are microbiota-
derived metabolites, were sufficient to restore microglia
function in the absence of the microbiota, whereas loss of
individual PRRs did not affect microglial activation.74
The maturation of immune defences in the central ner-
vous system parallels recent work demonstrating that
microbiota-derived metabolites influences behaviour in
mice.75,76
Conclusion
Our view of the role played by microbes in our health
has been completely revised by recent studies of the
microbiota. This change in perspective has refocused our
thinking of microbes as purely disease-causing threats to
a more balanced perspective that incorporates microbes
that can cause infection with those that play a beneficial
and fundamental role in regulating many aspects of our
normal physiology. Communication between microbes
and host is mediated by the immune system. The
immune system is now increasingly viewed, therefore, as
a system whose normal role is to manage the microbiota
day-to-day to exploit its beneficial effects, while guarding
against the more occasional threats posed by infectious
organisms.
From this increased understanding of how the micro-
biota influences host defences there are a number of core
principles that are becoming apparent. (i) The effects of a
microbiota colonizing a specific tissue are not restricted
to that specific site. This is especially the case for the gas-
trointestinal tract, with bacteria at that site having an
influence on nearly every tissue in the body. (ii) The
interaction between the microbiota and immune system
is highly dynamic. Many experimental studies have shown
that depletion of the microbiota reduces the production
and function of many immune cells, but restoration of
the microbiota reverses many of these effects. The
immune system is therefore constantly gauging the
required degree of activation to efficiently manage the
microbiota and pathogenic microbes without wasting
resources. (iii) Pattern recognition receptors are con-
stantly engaged by the microbiota and are the first steps
in translating microbial signals into changes in host cell
behaviour. Engagement of PRRs occurs directly at colo-
nized environmental interfaces but can also occur in
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deeper non-mucosal host tissues. PRRs are therefore
being repositioned as homeostatic regulators of the
immune system and not solely as sentinels of infec-
tion.30,43 (iv) Not all members of the microbiota are
equal in their ability to regulate the immune system.
Members of the microbiota should not therefore be con-
sidered as simple packages of cell wall molecules that will
all lead to equivalent pattern recognition receptor activa-
tion. (v) Tissue-resident cells, exemplified by tissue
macrophages, assimilate signals from both local and distal
microbial populations. Furthermore, it is thought that in
addition to the microbiota, infection and vaccination also
leave lasting imprints on tissue-resident macrophages.30,77
The variety of different microbial encounters that the host
experiences over its life-course therefore defines the ‘set-
point’ of innate cell immune activation of a given tissue.
This could, in part, explain the large environmentally dri-
ven variation in immune cell number, responses to
cytokines, and vaccination found in humans.78
Despite rapid progress in understanding how the
microbiota helps to protect against infection there are still
many things that remain unclear. First, given that not all
microbes regulate the immune system equally there is still
limited information, apart from a restricted number of
examples of local interactions in the gastrointestinal tract,
on how different microbial groups influence various arms
of host defence. A deeper understanding of how different
members of the microbiota interact with innate immune
receptors, host cells and what aspects of immunity they
regulate is crucial to be able to fully harness the power of
the microbiota for therapeutic benefit in the future. Sec-
ond, only limited progress has been made in defining the
signals and cellular functions that are influenced by the
microbiota downstream of PRR activation. Third, it is
still poorly understood how the microbiota helps protect
against extra-intestinal infections in humans. Some stud-
ies in humans have shown that changes in the microbiota
are associated with changes in lung function and
asthma;79 however, the specific effect on host resistance
to lung infections remains unclear. By extension we have
little understanding of how disruption of the microbiota
by antibiotics at clinically relevant doses and durations
influence host defences outside the gastrointestinal tract.
Most mechanistic studies aimed at defining how the
microbiota influences different aspects of systemic immu-
nity have used prolonged treatment with broad-spectrum
antibiotics to deplete the microbiota. Although this is of
great experimental utility, it provides limited information
on how the microbiota disruption we experience when
we are given antibiotics to treat infections affects immune
function. Finally, as vaccination is the other major human
intervention, along with antibiotics in the battle against
infection, a more complete understanding of how the
microbiota regulates vaccine responses could identify new
ways to improve our defences against infectious disease.
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